SEMA3A and breast carcinoma: Decreased Sema3A expression has been proposed to lead to a trend of decreasing effectiveness in promoting osteoblast formation in bone metastases of human breast cancer cells, suggesting that decreased Sema3A may play an important role in bone loss [11].